164.24
price up icon3.95%   6.24
after-market アフターアワーズ: 164.24
loading
前日終値:
$158.00
開ける:
$154.09
24時間の取引高:
2.06M
Relative Volume:
2.34
時価総額:
$8.08B
収益:
$4.02B
当期純損益:
$-79.62M
株価収益率:
-105.61
EPS:
-1.5551
ネットキャッシュフロー:
$543.67M
1週間 パフォーマンス:
+3.46%
1か月 パフォーマンス:
-25.24%
6か月 パフォーマンス:
+3.63%
1年 パフォーマンス:
-0.46%
1日の値動き範囲:
Value
$151.31
$165.12
1週間の範囲:
Value
$146.33
$165.12
52週間の値動き範囲:
Value
$91.86
$228.88

Charles River Laboratories International Inc Stock (CRL) Company Profile

Name
名前
Charles River Laboratories International Inc
Name
セクター
Healthcare (1110)
Name
電話
781-222-6000
Name
住所
251 BALLARDVALE ST, WILMINGTON, MA
Name
職員
20,100
Name
Twitter
@criverlabs
Name
次回の収益日
2024-11-06
Name
最新のSEC提出書
Name
CRL's Discussions on Twitter

Compare CRL vs TMO, DHR, IDXX, A, WAT

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Diagnostics & Research icon
CRL
Charles River Laboratories International Inc
164.24 7.78B 4.02B -79.62M 543.67M -1.5551
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
515.12 192.95B 44.56B 6.73B 6.29B 17.74
Diagnostics & Research icon
DHR
Danaher Corp
211.25 147.43B 24.57B 3.60B 5.25B 5.0475
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
630.73 50.70B 4.30B 1.06B 1.04B 13.08
Diagnostics & Research icon
A
Agilent Technologies Inc
126.34 35.90B 6.95B 1.30B 1.15B 4.5696
Diagnostics & Research icon
WAT
Waters Corp
328.66 32.13B 3.17B 642.63M 539.81M 10.77

Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-12-15 アップグレード BofA Securities Neutral → Buy
2025-11-17 アップグレード Argus Hold → Buy
2025-11-06 アップグレード Robert W. Baird Neutral → Outperform
2025-10-06 アップグレード William Blair Mkt Perform → Outperform
2025-10-02 アップグレード Barclays Equal Weight → Overweight
2025-09-09 アップグレード Jefferies Hold → Buy
2025-07-09 アップグレード Citigroup Neutral → Buy
2025-05-23 アップグレード Redburn Atlantic Neutral → Buy
2025-05-14 アップグレード TD Cowen Hold → Buy
2025-05-08 アップグレード Evercore ISI In-line → Outperform
2025-03-21 ダウングレード Goldman Buy → Neutral
2025-03-04 アップグレード Citigroup Sell → Neutral
2025-03-03 アップグレード Redburn Atlantic Sell → Neutral
2025-01-22 ダウングレード William Blair Outperform → Mkt Perform
2025-01-17 ダウングレード UBS Buy → Neutral
2024-11-18 ダウングレード CLSA Hold → Underperform
2024-11-07 アップグレード CLSA Underperform → Hold
2024-10-23 開始されました CLSA Underperform
2024-10-14 開始されました Redburn Atlantic Sell
2024-10-07 ダウングレード Evercore ISI Outperform → In-line
2024-10-02 ダウングレード BofA Securities Buy → Neutral
2024-10-01 ダウングレード Citigroup Neutral → Sell
2024-08-08 ダウングレード JP Morgan Overweight → Neutral
2024-08-08 ダウングレード Robert W. Baird Outperform → Neutral
2024-06-28 ダウングレード Argus Buy → Hold
2024-06-07 開始されました Mizuho Neutral
2024-06-06 開始されました Goldman Buy
2024-02-15 ダウングレード Guggenheim Buy → Neutral
2023-09-13 開始されました TD Cowen Market Perform
2023-07-10 ダウングレード Citigroup Buy → Neutral
2023-02-23 アップグレード Guggenheim Neutral → Buy
2023-01-12 ダウングレード Jefferies Buy → Hold
2022-09-30 アップグレード Jefferies Hold → Buy
2022-08-25 開始されました Credit Suisse Outperform
2022-08-04 ダウングレード Morgan Stanley Overweight → Equal-Weight
2022-05-24 開始されました Guggenheim Neutral
2022-04-25 ダウングレード Jefferies Buy → Hold
2022-04-07 開始されました Stephens Overweight
2022-02-17 繰り返されました BofA Securities Buy
2022-02-17 アップグレード Citigroup Neutral → Buy
2022-02-17 繰り返されました Deutsche Bank Buy
2022-02-17 繰り返されました Morgan Stanley Overweight
2022-02-17 繰り返されました UBS Buy
2021-08-05 再開されました Credit Suisse Neutral
2020-12-16 ダウングレード Citigroup Buy → Neutral
2020-09-10 アップグレード Jefferies Hold → Buy
2020-07-01 アップグレード BofA Securities Neutral → Buy
2020-05-13 アップグレード UBS Neutral → Buy
2020-04-21 ダウングレード Jefferies Buy → Hold
2020-03-27 アップグレード Morgan Stanley Equal-Weight → Overweight
2020-03-02 開始されました Deutsche Bank Buy
2020-02-18 アップグレード Wolfe Research Peer Perform → Outperform
2020-01-10 アップグレード Goldman Neutral → Buy
2020-01-08 開始されました Wells Fargo Overweight
2020-01-07 開始されました Citigroup Buy
2019-10-18 ダウングレード BofA/Merrill Buy → Neutral
2019-06-10 開始されました SVB Leerink Outperform
2019-04-30 再開されました Evercore ISI Outperform
2018-12-14 開始されました Deutsche Bank Buy
2018-10-09 開始されました UBS Neutral
2018-08-23 アップグレード Raymond James Mkt Perform → Outperform
2018-07-17 アップグレード RBC Capital Mkts Sector Perform → Outperform
2018-06-15 アップグレード KeyBanc Capital Mkts Sector Weight → Overweight
2018-02-14 アップグレード SunTrust Hold → Buy
すべてを表示

Charles River Laboratories International Inc (CRL) 最新ニュース

pulisher
01:37 AM

Charles River Laboratories NYSE CRL Quarterly Profit Streak Tests Bearish Profitability Narrative - simplywall.st

01:37 AM
pulisher
09:12 AM

Assessing Charles River Laboratories (CRL) Valuation After Recent Share Price Weakness - Yahoo Finance

09:12 AM
pulisher
08:15 AM

Charles River Laboratories International, Inc. (NYSE:CRL) Q4 2025 Earnings Call Transcript - Insider Monkey

08:15 AM
pulisher
06:26 AM

CenterBook Partners LP Raises Position in Charles River Laboratories International, Inc. $CRL - MarketBeat

06:26 AM
pulisher
01:04 AM

Strategic Review at Charles River Laboratories Raises Deal Uncertainty, Execution Risks, and Shareholder Value Concerns - TipRanks

01:04 AM
pulisher
12:12 PM

Decoding Charles River Laboratories International Inc (CRL): A S - GuruFocus

12:12 PM
pulisher
Feb 18, 2026

Charles River Laboratories (CRL) Exceeds Q4 Revenue Expectations with Strategic Growth - GuruFocus

Feb 18, 2026
pulisher
Feb 18, 2026

Charles River (CRL) Anticipates Steady Revenue Growth through FY - GuruFocus

Feb 18, 2026
pulisher
Feb 18, 2026

The Bull Case For Charles River Laboratories (CRL) Could Change Following 2025 Losses And New Leadership Appointments - Yahoo Finance

Feb 18, 2026
pulisher
Feb 18, 2026

Charles River Laboratories (CRL) Appoints New Chief Financial Of - GuruFocus

Feb 18, 2026
pulisher
Feb 18, 2026

Glenn Coleman and Kerry Dailey to join Charles River Labs leadership By Investing.com - Investing.com South Africa

Feb 18, 2026
pulisher
Feb 18, 2026

Why Charles River Labs Stock Is Sliding Today - TipRanks

Feb 18, 2026
pulisher
Feb 18, 2026

Charles River Labs Eyes Margin Gains Amid Flat Growth - TipRanks

Feb 18, 2026
pulisher
Feb 18, 2026

Charles River Labs Appoints Glenn Coleman as New CFO - TipRanks

Feb 18, 2026
pulisher
Feb 18, 2026

Charles River Laboratories International Inc (CRL) Q4 2025 Earni - GuruFocus

Feb 18, 2026
pulisher
Feb 18, 2026

Charles River projects up to 9% EPS growth in 2026 as new CEO, acquisitions, and cost savings drive margin expansion - MSN

Feb 18, 2026
pulisher
Feb 18, 2026

Glenn Coleman and Kerry Dailey to join Charles River Labs leadership - Investing.com Nigeria

Feb 18, 2026
pulisher
Feb 18, 2026

Charles River Laboratories International (NYSE:CRL) Shares Gap DownWhat's Next? - MarketBeat

Feb 18, 2026
pulisher
Feb 18, 2026

JPMorgan Cuts Charles River Laboratories International Price Target to $165 From $190, Maintains Neutral Rating - marketscreener.com

Feb 18, 2026
pulisher
Feb 18, 2026

Charles River Lab Taps Veteran Atty For New CLO Post - Law360

Feb 18, 2026
pulisher
Feb 18, 2026

Charles River Laboratories Q4 2025 earnings preview - MSN

Feb 18, 2026
pulisher
Feb 18, 2026

C-suite changes continue at Charles River with new CFO, legal chief - The Business Journals

Feb 18, 2026
pulisher
Feb 18, 2026

Charles River Laboratories International Q4 Earnings Call Highlights - MarketBeat

Feb 18, 2026
pulisher
Feb 18, 2026

Laboratory Giant Charles River Reels-in Alcon Lawyer for New CLO Post - Law.com

Feb 18, 2026
pulisher
Feb 18, 2026

New Charles River Leaders May Shape Valuation, Debt And Governance Outlook - simplywall.st

Feb 18, 2026
pulisher
Feb 18, 2026

Charles River Laboratories International, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance

Feb 18, 2026
pulisher
Feb 18, 2026

Charles River Laboratories Q4 Review: Approaching A Bottom (NYSE:CRL) - Seeking Alpha

Feb 18, 2026
pulisher
Feb 18, 2026

CRL: 2026 outlook projects margin and EPS growth, with DSA recovery and cost savings offsetting early headwinds - TradingView

Feb 18, 2026
pulisher
Feb 18, 2026

Charles River (CRL) Earnings Call Transcript - AOL.com

Feb 18, 2026
pulisher
Feb 18, 2026

Charles River Laboratories Announces Executive Appointments - PharmiWeb.com

Feb 18, 2026
pulisher
Feb 18, 2026

Charles River Laboratories International (NYSE:CRL) Issues Quarterly Earnings Results - MarketBeat

Feb 18, 2026
pulisher
Feb 18, 2026

Charles River Laboratories International (NYSE:CRL) Issues FY 2026 Earnings Guidance - MarketBeat

Feb 18, 2026
pulisher
Feb 18, 2026

Charles River Laboratories (CRL) Q4 revenue, adjusted earnings top expectations - AlphaStreet News

Feb 18, 2026
pulisher
Feb 18, 2026

Here's What Key Metrics Tell Us About Charles River (CRL) Q4 Earnings - Yahoo Finance

Feb 18, 2026
pulisher
Feb 18, 2026

Charles River Laboratories International, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 27, 2025 - marketscreener.com

Feb 18, 2026
pulisher
Feb 18, 2026

CRL Stock Down Despite Q4 Earnings & Revenue Beat, Margins Rise - TradingView

Feb 18, 2026
pulisher
Feb 18, 2026

Charles River Laboratories International, Inc. Announces Chief Financial Officer Changes, Effective April 6, 2026 - marketscreener.com

Feb 18, 2026
pulisher
Feb 18, 2026

Charles River Laboratories (NYSE:CRL) Beats Q4 CY2025 Sales Expectations - Finviz

Feb 18, 2026
pulisher
Feb 18, 2026

Charles River: Q4 Earnings Snapshot - KVUE

Feb 18, 2026
pulisher
Feb 18, 2026

Charles River Laboratories (CRL) Q4 Earnings and Revenues Surpass Estimates - Yahoo Finance

Feb 18, 2026
pulisher
Feb 18, 2026

Charles River forecasts upbeat 2026 profit on improved demand for drug development services - marketscreener.com

Feb 18, 2026
pulisher
Feb 18, 2026

Charles River Q4 Adjusted Earnings, Revenue Decline; New CFO Named - marketscreener.com

Feb 18, 2026
pulisher
Feb 18, 2026

CHARLES RIVER LABS INTL ($CRL) Releases Q4 2025 Earnings - Quiver Quantitative

Feb 18, 2026
pulisher
Feb 18, 2026

Charles River Laboratories 8-K Filing Analysis - TradingView

Feb 18, 2026
pulisher
Feb 18, 2026

Charles River Laboratories earnings beat by $0.04, revenue topped estimates - Investing.com Canada

Feb 18, 2026
pulisher
Feb 18, 2026

CRL: Non-cash impairments drove GAAP losses, but 2026 guidance anticipates EPS growth - TradingView

Feb 18, 2026
pulisher
Feb 18, 2026

Charles River Laboratories announces executive appointments - marketscreener.com

Feb 18, 2026
pulisher
Feb 18, 2026

Charles River Labs beats Q4 expectations, provides cautious 2026 outlook - Investing.com

Feb 18, 2026
pulisher
Feb 18, 2026

Charles River names Glenn Coleman as CFO, Kerry Dailey as CLO - StreetInsider

Feb 18, 2026
pulisher
Feb 18, 2026

Charles River Laboratories Announces Fourth-Quarter and Full-Year 2025 Results and Provides 2026 Guidance - Business Wire

Feb 18, 2026
pulisher
Feb 18, 2026

Charles River Laboratories International, Inc. (NYSE: CRL) Q4 2025 earnings call transcript - MSN

Feb 18, 2026

Charles River Laboratories International Inc (CRL) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
diagnostics_research DGX
$202.44
price down icon 0.95%
diagnostics_research LH
$282.48
price up icon 1.33%
diagnostics_research MTD
$1,376.53
price up icon 0.07%
diagnostics_research IQV
$169.36
price down icon 0.99%
$216.36
price up icon 0.39%
diagnostics_research WAT
$328.66
price up icon 0.35%
大文字化:     |  ボリューム (24 時間):